MS patients in Scotland must pay for treatment

Patients with relapsing remitting MS (RRMS) cannot be given natalizumab (Tysabri) on the NHS in Scotland despite good clinical outcomes because it is too expensive.

The Scottish Medicines Consortium (SMC) said that the economic case for providing the drug on the NHS has not been demonstrated.

It calculated that the cost per quality adjusted life year (QALY) for natalizumab is £32,000 com-pared with beta interferon and £31,000 compared with glatiramer acetate.

But the SMC acknowledged that clinical evidence showed that, compared with placebo, natalizumab significantly reduced relapse rate in patients with rapidly evolving severe RRMS. Sustained progression of disability over two years was also significantly less likely in patients given natalizumab.

Natalizumab is believed to reduce inflammation and demyelination in MS by inhibiting migration of leukocytes into the central nervous system. It is licensed as a single disease modifying therapy in highly active relapsing remitting MS (RRMS) if patients have rapidly developing disease or do not respond to beta interferon.

MS charities said the decision left doctors with no treatment al-ternatives for these patients.

Patients will only be able to receive natalizumab if they fund the drug themselves or if Scottish health boards take the unusual step of overruling the SMC advice.

Chief executive of the MS Trust Chris Jones said: ‘Clinicians will be prevented from prescribing an effective licensed treatment to people in need. We urge people with MS to continue fighting for Tysabri on an individual basis.’

Mark Hazelwood, director of the MS Society Scotland, said: ‘No other drug has shown this poten-tial to reduce disability and any short-term savings are likely to be outpaced by the devastating financial costs of living with severe, progressive disability.

‘Longer-term, we are concerned about the implications this might have on the forthcoming NICE decision this summer,’ he added.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...

Expansion of NHS 111 service could see direct GP booking extended

Expansion of NHS 111 service could see direct GP booking extended

Plans to expand NHS 111 under measures to prepare the health service for winter could...